Insilico inks another deal with Sino Biopharma unit; Ramaswamy's Datavant to invest in the "patient journey"
→ Insilico — the well-connected AI drug discovery shop that has raised funds at the behest of Shanghai high-flyer WuXi AppTec, Singapore’s Temasek, Peter Diamandis, and Juvenescence — has signed its second deal with a Sino Biopharmaceutical subsidiary. The agreement is with Beijing Tide Pharmaceutical and will focus on cancer drug discovery.
The size of the deal is considerable and is comparable to our previous deal with CTFH, co-founder Alex Zhavoronkov told Endpoints News. The two-program AI drug discovery collaboration inked in 2019 with CTFH made Insilico eligible to receive up to $200 million in milestone payments and royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
